Viking Therapeutics says its experimental tablet reduced weight in early-stage studyReuters • 03/26/24
Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735PRNewsWire • 03/26/24
2 Soaring Growth Stocks That Could Climb Another 47% to 73%, According to Wall StreetThe Motley Fool • 03/26/24
Viking Therapeutics Stock Has 55% Upside, According to 1 Wall Street AnalystThe Motley Fool • 03/21/24
Should Pfizer Acquire Viking Therapeutics to Take on Eli Lilly and Novo Nordisk in the Obesity Drug Market?The Motley Fool • 03/15/24
Could Viking Therapeutics Challenge Giant Eli Lilly in the Billion-Dollar Weight-Loss Drug Market?The Motley Fool • 03/13/24
Missed Out on Eli Lilly and Novo Nordisk? This Could Be the Next Big Weight Loss Stock.The Motley Fool • 03/09/24
Viking Therapeutics faces higher bar for oral weight-loss drug after strong readout from rivalMarket Watch • 03/08/24
Is Viking Therapeutics Stock a Better Buy Than Eli Lilly and Novo Nordisk After the Latest Weight-Loss Drug News?The Motley Fool • 03/06/24